NeoImmuneTech, US think tank to develop treatment for acute radiation syndrome

The company could supply its technology to the American government after confirming its effect

Yang Se-hwan, CEO of NeoImmuneTech 
Yang Se-hwan, CEO of NeoImmuneTech 
Jae-Young Han 1
2023-01-04 09:23:16 jyhan@hankyung.com
Bio & Pharma

Biopharmaceutical company NeoImmuneTech has grabbed an opportunity to supply new drug candidates in development as strategic items to the US government.

NeoImmuneTech on Tuesday said it signed a research and development agreement to work on treatment for acute radiation syndrome (ARS) with the National Institute of Allergy and Infectious Diseases(NIAID) under the National Institutes of Health (NIH) based in Washington, DC.

ARS is a disease that can occur due to exposure to a large dose of penetrating radiation through incidents like a terrorist attack that damages the immune system. The rapid drop in platelets and immune cells such as neutrophils and lymphocytes exposes the body to a host of infections.

NeoImmuneTech has developed anticancer drugs with its candidate substance NT-I7 that amplifies T cell lymphocytes to maximize attacks on cancer cells by boosting the volume of immunocytes. NIAID will develop NT-I7 to raise the number of lymphocytes when the latter is reduced by radiation exposure.

NeoImmuneTech expects to sign an NT-I7 supply contract around 2025 if NT-I7's effect is confirmed.

"We will seek to supply (NT-I7) to Europe as a strategic item," NeoImmuneTech CEO Yang Se-hwan said. “The US government's recognition of the effect of T-cell amplification will have a positive impact on the approval of anticancer drugs," he added.

Write to Jae-Young Han at jyhan@hankyung.com
#NeoImmuneTech #acute radiation syndrome (ARS) #US #National Institute of Allergy and Infectious Diseases(NIAID) #National Institutes of Health (NIH) #NT-I7

CJ applies to FDA for trials of immuno-anticancer drug candidate

CJ applies to FDA for trials of immuno-anticancer drug candidate

CJ Bioscience, an independent red bio (pharmaceutical and healthcare) subsidiary of CJ CheilJedang Corp., said on Monday it has submitted a phase 1 and 2 clinical trial protocol for CJRB-101, an immuno-anticancer drug candidate, to the US Food and Drug Administration (FDA). CJRB-101 is a

S. Korea's GI Cell, Japanese partner to study cell therapy for blood cancer

S. Korea's GI Cell, Japanese partner to study cell therapy for blood cancer

South Korea's GI Cell, the cell therapy affiliate of GI Innovation, on Tuesday said it signed an agreement with Optieum Biotechnologies of Japan on joint research in blood cancer.Optieum is developing a platform to find a single-chain fragment variable (ScFv) structure that boosts the effects

Hanmi’s anti-cancer drug Rolontis gets FDA approval; US sale via Spectrum

Hanmi’s anti-cancer drug Rolontis gets FDA approval; US sale via Spectrum

Rolontis, a neutropenia agent, will be sold in the US under the Rolvedon brand South Korea’s Hanmi Pharmaceutical Co. said on Tuesday that Rolontis, an anti-cancer drug it has jointly developed with its US partner, has obtained marketing approval from the US Food and Drug Administration.T

LG Chem receives FDA nod for CUE-102 cancer treatment phase 1 trials

LG Chem receives FDA nod for CUE-102 cancer treatment phase 1 trials

LG Chem researchers LG Chem Life Sciences, the biopharmaceutical unit of LG Chem Ltd., has received the US Food and Drug Administration’s approval for phase 1 clinical tests of its cancer treatment candidate CUE-102.The South Korean company said on Thursday the clinical trials will be con
(* comment hide *}